The 32-person company, in R&D mode since 2006 and poised for commercialization this year, just completed large clinical studies to validate its technology ??? a non-invasive functional brain mapping to diagnose and monitor cognitive impairments such as in Alzheimer???s and Parkinson diseases, ADHD, brain injuries and other neurological disorders affecting millions of people.